Company intelligence / Profile preview

Abintus Bio

San Diego, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Developing in vivo CAR-X products that simultaneously target both adaptive and innate immune effector cells to produce immune responses against tumors. Initial products were poised to enter clinical evaluation as early as 2023.

Therapeutic areas: OncologyRare DiseasesImmunologyInfectious Diseases
Modalities: In vivo CAR-X productsgenetic medicines
Industry: Biotech

Drug pipeline

1 asset

ABIN-19

Preclinical

Partnerships

Memorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on Abintus Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abintus Bio.

Explore the full profile